A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension.

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Azilsartan (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 24 Jan 2009 Planned number of patients (555) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top